The CDC's recent decision to discontinue testing for rabies and monkeypox has sparked concern among infectious disease specialists, who warn that the move could slow down critical diagnoses and weaken the nation's ability to track emerging outbreaks. As state public health laboratories step up to fill the gap, questions remain about whether they have the resources and capacity to handle the increased demand .

What's Behind the CDC's Testing Pause?

In a significant shift in public health infrastructure, the CDC has paused its testing services for several pathogens, including rabies and monkeypox, according to recent clinical updates from infectious disease experts. The agency's reasoning and timeline for resuming these services remain unclear, leaving state laboratories to shoulder the responsibility. This decision comes at a time when the nation is already grappling with multiple concurrent infectious disease challenges, including a measurable uptick in measles cases and ongoing circulation of respiratory viruses like influenza, RSV (respiratory syncytial virus), and COVID-19 .

The pause also coincides with changes to the CDC's Advisory Committee on Immunization Practices (ACIP), which oversees vaccine recommendations for the nation. The committee's charter has been revised, raising questions about how these structural changes might affect future vaccine policy and disease prevention strategies .

How Are State Labs Responding to the Testing Gap?

State public health laboratories are now taking on expanded testing responsibilities for pathogens that were previously handled by the CDC. This decentralization of testing authority represents a significant operational shift in how the United States monitors and responds to infectious disease threats. While state labs have demonstrated their capacity to conduct sophisticated testing, experts worry about whether all states have equal resources and expertise to maintain consistent, rapid turnaround times for critical diagnoses like rabies, which requires immediate intervention to prevent fatal outcomes .

The transition also raises concerns about data standardization and reporting consistency across states. When testing is fragmented across multiple laboratories, tracking national trends and identifying emerging outbreaks becomes more challenging for public health officials and clinicians.

What Other Infectious Disease Threats Are Competing for Attention?

The CDC's testing pause arrives during a period of heightened infectious disease activity. Recent developments include:

• Measles Outbreak: The United States is experiencing measles cases among unvaccinated populations, with US scientists sequencing over 1,000 measles genomes to track the disease's spread and genetic evolution, despite measles being officially eliminated in the country decades ago .
• Respiratory Virus Circulation: Influenza, RSV, and SARS-CoV-2 continue to circulate, with wastewater surveillance systems tracking these pathogens across the nation to provide early warning of surges .
• Foodborne Illness Outbreaks: An outbreak of E. coli illness linked to raw cheese has prompted FDA recalls and raised questions about food safety oversight, with ongoing investigations into the source and scope of contamination .
• Antimicrobial Resistance: Drug-resistant strains of bacteria, including Shigella, are emerging in various regions, complicating treatment options and underscoring the broader challenge of antibiotic resistance .

Why Should Patients and Clinicians Care About This Change?

For patients, the practical impact of the CDC's testing pause could mean longer wait times for rabies confirmation, which is critical because rabies is nearly 100% fatal once symptoms appear. Early diagnosis and post-exposure prophylaxis (PEP) can prevent the disease, but delays in testing could jeopardize outcomes. Similarly, monkeypox diagnosis and tracking could be affected, potentially complicating efforts to contain outbreaks and monitor variants .

Clinicians may also face challenges accessing testing resources, particularly in rural or under-resourced areas where state laboratory capacity is limited. This fragmentation of testing authority could create a two-tiered system where patients in well-funded states receive faster diagnoses than those in states with fewer resources.

Steps to Stay Informed About Infectious Disease Risks

• Monitor Wastewater Data: The CDC's Wastewater Scan dashboard provides real-time tracking of 11 pathogens, including influenza, RSV, and COVID-19, allowing individuals to understand local disease circulation patterns and adjust precautions accordingly .
• Check Vaccination Status: Ensure you and your family are up to date on recommended vaccines, particularly measles, mumps, and rubella (MMR), influenza, and RSV vaccines for older adults, as these remain effective tools for preventing serious illness .
• Know When to Seek Testing: If you experience symptoms of rabies exposure (such as animal bites or scratches), seek immediate medical attention rather than waiting for test results, as post-exposure prophylaxis must be administered quickly to be effective .
• Stay Updated on Outbreaks: Use the Johns Hopkins measles tracker and CDC respiratory illness dashboards to stay informed about disease activity in your region and make informed decisions about gatherings and travel .

The CDC's decision to pause testing for rabies and monkeypox represents a significant shift in how the nation's public health infrastructure operates. While state laboratories are stepping up to meet the challenge, experts emphasize the importance of maintaining robust, well-resourced testing capacity across all regions. As infectious disease threats continue to evolve, the ability to quickly diagnose and track pathogens remains essential to protecting public health.